GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (GREY:ARBQY) » Definitions » Cyclically Adjusted Revenue per Share

Aurobindo Pharma (Aurobindo Pharma) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aurobindo Pharma Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Aurobindo Pharma's adjusted revenue per share for the three months ended in Mar. 2024 was $1.540. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Aurobindo Pharma's average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Aurobindo Pharma was 11.70% per year. The lowest was 11.60% per year. And the median was 11.65% per year.

As of today (2024-06-24), Aurobindo Pharma's current stock price is $0.00. Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.00. Aurobindo Pharma's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aurobindo Pharma was 3.35. The lowest was 1.08. And the median was 2.16.


Aurobindo Pharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Aurobindo Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cyclically Adjusted Revenue per Share Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aurobindo Pharma's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cyclically Adjusted PS Ratio falls into.



Aurobindo Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurobindo Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.54/153.0345*153.0345
=1.540

Current CPI (Mar. 2024) = 153.0345.

Aurobindo Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.835 94.103 1.358
201409 0.811 96.780 1.282
201412 0.864 96.780 1.366
201503 0.843 97.163 1.328
201506 0.886 99.841 1.358
201509 0.870 101.753 1.308
201512 0.902 102.901 1.341
201603 0.958 102.518 1.430
201606 0.956 105.961 1.381
201609 0.972 105.961 1.404
201612 0.984 105.196 1.431
201703 0.946 105.196 1.376
201706 0.974 107.109 1.392
201709 1.174 109.021 1.648
201712 1.152 109.404 1.611
201803 1.062 109.786 1.480
201806 1.071 111.317 1.472
201809 1.122 115.142 1.491
201812 1.246 115.142 1.656
201903 1.278 118.202 1.655
201906 1.318 120.880 1.669
201909 1.321 123.175 1.641
201912 1.391 126.235 1.686
202003 1.388 124.705 1.703
202006 1.315 127.000 1.585
202009 1.481 130.118 1.742
202012 1.473 130.889 1.722
202103 1.404 131.771 1.631
202106 1.320 134.084 1.507
202109 1.365 135.847 1.538
202112 1.356 138.161 1.502
202203 1.298 138.822 1.431
202206 1.350 142.347 1.451
202209 1.207 144.661 1.277
202212 1.322 145.763 1.388
202303 1.323 146.865 1.379
202306 1.410 150.280 1.436
202309 1.469 151.492 1.484
202312 1.491 152.924 1.492
202403 1.540 153.035 1.540

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Aurobindo Pharma  (GREY:ARBQY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Aurobindo Pharma was 3.35. The lowest was 1.08. And the median was 2.16.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Aurobindo Pharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (Aurobindo Pharma) Business Description

Industry
Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (Aurobindo Pharma) Headlines